)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Autolus Therapeutics
Autolus Therapeutics (AUTL) investor relations material
Autolus Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary14 Sep, 2026
Company overview and business model
Commercial-stage biopharmaceutical company focused on next-generation T cell therapies for cancer and autoimmune diseases, leveraging proprietary T cell programming technologies.
Lead product AUCATZYL (obe-cel) approved by FDA in November 2024 for adult relapsed/refractory B-cell precursor acute lymphoblastic leukemia (r/r B-ALL); commercial launches in the US (Jan 2025) and UK (Jan 2026).
Obe-cel is also in development for pediatric B-ALL, B-NHL, and autoimmune indications, with ongoing clinical trials and promising early data.
Manufacturing centralized at the Nucleus facility in Stevenage, UK, with Cardinal Health as US distribution partner.
Financial performance and metrics
Financial statements for the year ended December 31, 2025, audited by Ernst & Young LLP, are incorporated by reference.
Company voluntarily files detailed periodic reports on US domestic issuer forms, providing extensive financial disclosures.
Use of proceeds and capital allocation
Will not receive proceeds from the resale of ADSs by the selling securityholder; proceeds from warrant exercise ($1.9314 per ADS) will be received if exercised for cash.
Registration costs borne by the company; selling securityholder pays underwriting fees, commissions, and certain legal expenses.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Autolus Therapeutics
- Strong revenue growth, clinical success, and pipeline expansion drive future value.AUTL
Corporate presentation - Q2 2026 revenue surged 119% year-over-year, with gross margin at 55% and guidance raised.AUTLQ2 2026
- Obe-cel delivers durable remissions in adult ALL, with persistence driving long-term outcomes.AUTLStatus Update
- AUCATZYL's U.S. launch exceeds expectations, with expansion into Europe and autoimmune indications advancing.AUTLGoldman Sachs 46th Annual Global Healthcare Conference
- Expanding CAR T-cell therapy demonstrates robust efficacy, safety, and broadening market reach.AUTLH.C. Wainwright 4th Annual Cell Therapy Virtual Conference
- Strong commercial growth and pipeline progress, with high remission rates and expanding indications.AUTL46th Annual William Blair Growth Stock Conference
- Lead CAR-T therapy sees robust growth, margin gains, and broadening clinical impact.AUTLJefferies Global Healthcare Conference 2026
- Obe-cel advances in B-ALL and lupus nephritis, with pivotal trials and EU/UK reviews ahead.AUTLStatus Update
- AUCATZYL's US launch drove $9M Q1 revenue, UK approval, and pivotal trials in LN and MS ahead.AUTLQ1 2025
Next Autolus Therapeutics earnings date
Q3 202610 Nov, 2026
Autolus Therapeutics
Next Autolus Therapeutics earnings date
Q3 202610 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Autolus Therapeutics plc is a clinical-stage biopharmaceutical company engaged in the development of advanced T-cell therapies for the treatment of cancer. The company leverages its proprietary technologies to engineer CAR T-cell therapies aimed at providing life-changing benefits to patients with various cancer types. Some of their key clinical-stage programs focus on therapies for conditions such as adult acute lymphoblastic leukemia and multiple myeloma. Autolus was founded in 2014, following innovative developments in cell programming technology at University College London. The company is headquartered in London, United Kingdom, and its shares are listed on the Nasdaq.